How GLP-1 Works

In the space of about five years, a family of peptide drugs — semaglutide, tirzepatide, and now retatrutide — went from niche diabetes medications to the most-talked-about weight loss drugs in history. They all work by mimicking a hormone called GLP-1 that your own gut makes every time you eat.

The interesting question isn't why they cause weight loss. That's now well documented. The interesting question is: what does GLP-1 actually do in a normal body, and why does mimicking it produce such dramatic results?

The natural system

Your gut makes dozens of hormones. Most people don't think of it as an endocrine organ, but it is — by mass, one of the largest in the body. When you eat, specialized cells in your small intestine release hormones that tell the rest of your body that food has arrived.

GLP-1 (glucagon-like peptide-1) is one of those hormones. It's released by L-cells in the lower small intestine about 15 minutes after you start eating, and it does four things:

1. Tells the pancreas to release insulin — but only if blood sugar is elevated.
2. Tells the pancreas to stop releasing glucagon, the hormone that raises blood sugar.
3. Slows down how fast food leaves your stomach.
4. Tells your brain you're full.

This is a beautifully designed meal-response system. Your gut detects food, coordinates the pancreas's blood sugar response, paces the meal so nothing overwhelms you, and tells your appetite to wind down. It's the reason a meal makes you feel full long before your stomach is actually stretched.

Why it's glucose-dependent

One quirk matters a lot for safety: GLP-1 only nudges the pancreas to release insulin when blood sugar is actually high. If your blood sugar is normal, GLP-1 doesn't force extra insulin out.

This is why GLP-1 drugs generally don't cause hypoglycemia on their own, unlike older diabetes drugs that push insulin release regardless of blood sugar. The pancreatic beta cell needs both signals — elevated glucose and GLP-1R activation — to dump insulin. GLP-1 is an amplifier, not a trigger.

Why natural GLP-1 isn't a drug

If GLP-1 is so useful, why not just inject GLP-1 itself?

Because GLP-1's half-life is about two minutes. An enzyme in your blood called DPP-IV chops off the first two amino acids, and the resulting fragment no longer binds the receptor. Natural GLP-1 barely makes it out of the gut's local circulation before it's destroyed.

Every GLP-1 drug is a chemistry project aimed at fixing that problem:

Drug	Half-life	How it survives
Native GLP-1	2 minutes	(It doesn't.)
Exenatide	~2.5 hr	Copied from Gila monster venom; naturally DPP-IV resistant
Liraglutide (Saxenda)	~13 hr	Fatty acid tail, binds albumin
Dulaglutide (Trulicity)	~5 days	Fused to an antibody fragment
Semaglutide (Ozempic)	~7 days	Stronger fatty acid anchor + protease-resistant swaps
Tirzepatide (Mounjaro)	~5 days	Same trick, plus a second receptor
Retatrutide	~6 days	Same trick, plus two more receptors

The trick is always the same: make it too stable for DPP-IV, too sticky to leave albumin, and too big for the kidneys to filter quickly.

How the weight loss happens

The blood sugar effects explain why these drugs work for type 2 diabetes. The weight loss is mostly a separate story.

GLP-1 receptors aren't just in your pancreas and gut. They're also in your hypothalamus and brainstem — the parts of your brain that run hunger. When a weekly dose of semaglutide keeps those receptors activated around the clock, three things happen:

1. Gastric emptying slows. Food sits in your stomach longer, so you feel full for hours after eating. This is where the "I ate three bites and I'm done" experience comes from.
2. Appetite signals dim. The brain circuits that normally drive hunger — NPY/AgRP neurons in the arcuate nucleus — go quieter. The ones that drive satiety (POMC/CART) go louder.
3. Food reward changes. People frequently report that food just isn't as interesting. The dopamine response to eating is blunted. This is a central effect, not a gut effect.

The net result is a large, sustained drop in daily calories — not because people are disciplined, but because their hunger system has been rewired for the duration of the drug's effect.

Why Sema, Tirze, and Reta aren't the same

People lump these together, but they target different numbers of receptors:

• Semaglutide (Ozempic, Wegovy): GLP-1 receptor only.
• Tirzepatide (Mounjaro, Zepbound): GLP-1 and GIP receptors. GIP is another incretin — it works alongside GLP-1 but has different effects on fat tissue. The combination appears to improve the drug's effect on lipids, hunger, and (per head-to-head trials) total weight loss.
• Retatrutide: GLP-1, GIP, and glucagon receptors. The glucagon piece is the wild one — glucagon raises metabolic rate and mobilizes fat stores, so retatrutide pushes weight loss from both sides (eat less, burn more). Trial data so far shows the largest weight loss of the class.

More receptors isn't strictly "better." Each receptor adds effects, including side effect profiles. The trade-off is what clinical trials are working out in real time.

Practical implications

Titration is mandatory. Because GLP-1 drugs slow gastric emptying and cause nausea, everyone starts at a sub-therapeutic dose and steps up over weeks or months. Going straight to the maintenance dose causes most people to vomit, skip meals entirely, and quit.

Steady state takes weeks. With a ~7-day half-life, semaglutide needs about five weeks of weekly dosing to reach steady state. Effects usually plateau around month 2–3.

Meals matter less. Unlike GH peptides, GLP-1 drugs don't need to be timed around food. They're active around the clock.

Muscle loss is a real concern. Because appetite drops so sharply, people often eat far too little protein. Resistance training and deliberate protein intake (1.0+ g/lb bodyweight) are the most consistent advice in the community for preserving lean mass while losing fat.

Where to go next

• For the receptor-level biology, Pepperpedia has detailed entries on GLP-1 receptor signaling and the broader incretin system.
• For the compound-specific guide, see Semaglutide (Ozempic / Wegovy).
• For why the half-life numbers above matter for dosing, Half-Life and Why It Matters.
• For the receptor-binding model underneath all of this, How Peptides Signal in the Body.